Clinical Perspectives on Real-World Utility and Impact of Epinephrine Nasal Spray
A panelist discusses how Neffy offers significant advantages over traditional autoinjectors including longer shelf life (24-30 months), better temperature tolerance, and needle-free administration that addresses several unmet needs in anaphylaxis management.
Video content above is prompted by the following:
This segment highlights Neffy's practical advantages over traditional autoinjectors, particularly regarding storage and shelf life. Dr. Dixit notes Neffy's significantly longer shelf life: 30 months for the 2mg dose and 24 months for the 1mg dose, compared to autoinjectors' shorter expiration periods. He also emphasizes Neffy's superior temperature tolerance, which enables more flexibility in storage conditions, though he still advises against extreme temperature exposure like leaving it in hot cars.
Dr. Dixit summarizes Neffy's key benefits in addressing unmet needs: needle-free delivery, improved portability, and ease of use. When asked about appropriate patient candidates for Neffy, Dr. Dixit challenges the notion that it's only for specific populations, suggesting it's suitable for all patients within approved parameters (ages 4+ with appropriate weight-based dosing). He cites its carrying convenience, storage advantages, and effectiveness as making it appropriate for general use.
Responding to audience questions about post-marketing experience, Dr. Dixit shares that while he lacks official data, his colleagues report positive clinical outcomes with Neffy, noting patients recover similarly or sometimes faster than with IM epinephrine administration. He also addresses questions about the pediatric 1mg dose, confirming it became available approximately two weeks prior and was developed based on pharmacokinetic studies showing blood concentration levels similar to those achieved with the 2mg adult dose.
